CRISPR Therapeutics chief legal officer retires
Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Zug, Switzerland-based CRISPR Therapeutics AG said Tyler Dylan-Hyde retired as chief legal officer of the company.
Dylan-Hyde joined the company in January 2015.
The company develops gene-editing therapies for various diseases, including sickle cell disease and hemophilia.
